---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-21-000033"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2021-12-23T23:59:59+00:00"
generated_at: "2026-06-27T22:38:41.790314+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Arcutis secures $225M non-dilutive debt facility; FDA accepts NDA for roflumilast cream (PDUFA July 2022)

## Summary
- $75M drawn at closing; additional $125M available upon FDA approval of roflumilast cream for plaque psoriasis; $25M upon revenue milestones.
- Loan maturity January 2027; interest-only period for entire five years; floating rate = 7.45% + 1M SOFR.
- FDA accepted NDA for roflumilast cream (psoriasis) with PDUFA target action date of July 29, 2022.
- Proceeds extend cash runway into 2024; non-dilutive financing from SLR Capital Partners.
- Loan secured by substantially all assets; prepayment premiums of 3%/2%/1% declining over time.

## SEC filing metadata
- accession: 0001787306-21-000033
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2021-12-23T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730621000033/0001787306-21-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730621000033/arqt-20211222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-21-000033
- JSON: https://secwatch.observer/filing/0001787306-21-000033.json
- Plain text: https://secwatch.observer/filing/0001787306-21-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.